We are live on ! Find out more
HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

Delisted

HZNP was delisted on the 5th of October, 2023.

611 hedge funds and large institutions have $21.8B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 228 increasing their positions, 215 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 46

42% more call options, than puts

Call options by funds: $123M | Put options by funds: $86.3M

7% more funds holding

Funds holding: 572611 (+39)

6% more repeat investments, than reductions

Existing positions increased: 228 | Existing positions reduced: 215

1% less capital invested

Capital invested by funds: $22B → $21.8B (-$248M)

30% less funds holding in top 10

Funds holding in top 10: 3021 (-9)

Holders
611
Holders Change
+39
Holders Change %
+6.82%
% of All Funds
9.4%
Holding in Top 10
21
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-30%
% of All Funds
0.32%
New
96
Increased
228
Reduced
215
Closed
46
Calls
$123M
Puts
$86.3M
Net Calls
+$36.3M
Net Calls Change
-$258M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.17B +$12.4M +113,681 +0.6%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$1.71B +$29.1M +266,560 +2%
BlackRock
3
BlackRock
New York
$1.4B -$55.4M -508,152 -4%
ACA
4
Avoro Capital Advisors
New York
$1B +$32.2M +295,000 +3%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$760M +$109M +998,456 +16%
N
6
Nuveen
North Carolina
$759M +$18.7M +171,736 +2%
JP Morgan Chase
7
JP Morgan Chase
New York
$655M +$29.1M +266,724 +5%
PC
8
Paulson & Co
New York
$647M -$18.5M -169,296 -3%
State Street
9
State Street
Massachusetts
$590M +$3.52M +32,291 +0.6%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$393M -$15M -137,507 -4%
VOYA Investment Management
11
VOYA Investment Management
Georgia
$324M -$34.8M -318,972 -10%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$313M +$9.89M +90,703 +3%
Allianz Asset Management
13
Allianz Asset Management
Germany
$305M -$19.5M -178,732 -6%
O
14
OrbiMed
New York
$269M -$12M -110,300 -4%
PAMS
15
Pictet Asset Management (Switzerland)
Switzerland
$254M +$11.7M +107,291 +5%
William Blair Investment Management
16
William Blair Investment Management
Illinois
$251M -$85.7M -785,682 -25%
Norges Bank
17
Norges Bank
Norway
$251M +$22.5M +206,182 +10%
Renaissance Technologies
18
Renaissance Technologies
New York
$245M -$106M -974,397 -30%
Ameriprise
19
Ameriprise
Minnesota
$230M -$45.5M -417,027 -16%
Franklin Resources
20
Franklin Resources
California
$212M +$10.2M +93,266 +5%
Fidelity International
21
Fidelity International
Bermuda
$197M +$120M +1,101,141 +151%
Aberdeen Group
22
Aberdeen Group
United Kingdom
$197M -$4.63M -42,486 -2%
Macquarie Group
23
Macquarie Group
Australia
$190M +$14.5M +132,842 +8%
PA
24
Perceptive Advisors
New York
$187M -$23.9M -218,800 -11%
Northern Trust
25
Northern Trust
Illinois
$180M +$343K +3,143 +0.2%

HZNP Hedge Fund Activity: Q4 2021 in Review

611 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q4 2021, worth a combined $21.8B — down 1.1% from $22B a quarter earlier.

Buyers outnumbered sellers: 96 funds opened new HZNP positions and 46 closed out — a net gain of 50 holders — while 228 added to existing stakes and 215 trimmed.

The largest buyer was Marshall Wace, adding an estimated $176M. The largest seller was Adage Capital Partners, cutting an estimated $191M.

  • 611 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q4 2021, up from 572 in Q3 2021.
  • Funds reported $21.8B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q4 2021, down 1.1% quarter-over-quarter.
  • 96 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q4 2021 and 46 closed out, a net change of +50 holders.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q4 2021 was Marshall Wace, an estimated $176M added.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q4 2021 was Adage Capital Partners, an estimated $191M sold.

Based on aggregated 13F filings for Q4 2021.